Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Everolimus
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Everolimus 5mg tablets
0801050AXAAAAAA
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | 4 |
|
Everolimus 250microgram tablets
0801050AXAAADAD
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | 1 |
|
Everolimus 750microgram tablets
0801050AXAAAEAE
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | 1 |
|
Everolimus 10mg tablets
0801050AXAAABAB
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Everolimus 2.5mg tablets
0801050AXAAACAC
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Everolimus 2mg dispersible tablets sugar free
0801050AXAAAGAG
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Everolimus 3mg dispersible tablets sugar free
0801050AXAAAHAH
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Everolimus 500microgram tablets
0801050AXAAAFAF
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Everolimus 5mg dispersible tablets sugar free
0801050AXAAAIAI
|
Everolimus | Everolimus | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.